Solid tumours and chromosome aberrations as late side effects of melphalan therapy in ovarian carcinoma.
Fifty-five ovarian cancer patients treated with melphalan during 1968-1978 were followed during 309 person years and studied with cytogenetic analyses. During the clinical follow-up 7 patients developed a new primary solid tumour. The excess risk of developing new primary solid tumours in patients treated with melphalan was statistically significant (p less than 0.05) and the relative risk corresponded to 3.0. Patients developing a new solid tumour showed a similar pattern of chromosome aberrations in the peripheral lymphocytes to that previously shown for the whole cohort.
Einhorn
N
N
Department of Gynecological Oncology, Karolinska Institute, Stockholm, Sweden.
Eklund
G
G
Lambert
B
B
D002478:Cells, Cultured; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000166:cytology; D008558:Melphalan / Q000009:adverse effects* / Q000627:therapeutic use; D009367:Neoplasm Staging; D009369:Neoplasms / Q000139:chemically induced* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012854:Sister Chromatid Exchange
D008558:Melphalan